These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 3168396)
1. The influence of verapamil and nifedipine on hepatic indocyanine green clearance in patients with HBsAg-positive cirrhosis and ascites. Lay CS; Tsai YT; Kong CW; Lee FY; Chang TT; Lin HC; Yang CM; Lee SD; Chiang BN; Lo KJ Clin Pharmacol Ther; 1988 Oct; 44(4):453-7. PubMed ID: 3168396 [TBL] [Abstract][Full Text] [Related]
2. [The effects of verapamil and nifedipine on the biotransformation of model substances and on the indocyanine green elimination]. Sigusch H; Henschel L; Hoffmann A Gastroenterol J; 1991; 51(1):33-6. PubMed ID: 1910493 [TBL] [Abstract][Full Text] [Related]
3. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy. Bauer LA; Stenwall M; Horn JR; Davis R; Opheim K; Greene L Clin Pharmacol Ther; 1986 Aug; 40(2):239-42. PubMed ID: 3731687 [TBL] [Abstract][Full Text] [Related]
4. Effects of verapamil on estimated hepatic blood flow in patients with HBsAg-positive cirrhosis. Lay CS; Tsai YT; Kong CW; Lee FY; Lee SD; Chen KY; Chiang BN; Lo KJ Hepatogastroenterology; 1988 Jun; 35(3):121-4. PubMed ID: 3402902 [TBL] [Abstract][Full Text] [Related]
5. The influence of vasoactive agents on metabolic activity of the liver in cirrhosis: a study of the effects of posterior pituitary extract, vasopressin, and somatostatin. Barbare JC; Poupon R; Jaillon P; Bories P; Aussanaire M; Darnis F; Michel H; Cheymol G Hepatology; 1984; 4(1):59-62. PubMed ID: 6141135 [TBL] [Abstract][Full Text] [Related]
6. Octreotide decreased liver metabolic activity in patients with hepatitis B surface antigen-positive cirrhosis. Lin HC; Tsai YT; Lee SD; Lee FY; Hsia HC; Meng HC; Wang SS; Lo KJ Clin Pharmacol Ther; 1992 Aug; 52(2):134-8. PubMed ID: 1354573 [TBL] [Abstract][Full Text] [Related]
7. Lack of effect of verapamil and isosorbide dinitrate on the hepatic clearance of indocyanine green in cirrhosis. Merkel C; Bolognesi M; Angeli P; Finucci GF; Amodio P; Bellon S; Gatta A Br J Clin Pharmacol; 1990 Aug; 30(2):221-7. PubMed ID: 2206784 [TBL] [Abstract][Full Text] [Related]
8. Verapamil pharmacokinetics and liver function in patients with cirrhosis. Finucci GF; Padrini R; Piovan D; Melica E; Merkel C; Gatta A; Zuin R Int J Clin Pharmacol Res; 1988; 8(2):123-6. PubMed ID: 3378854 [TBL] [Abstract][Full Text] [Related]
9. Verapamil has no effect on porto-hepatic pressure gradient, hepatic blood flow and elimination function of the liver in patients with liver cirrhosis. Vinel JP; Caucanas JP; Combis JM; Cales P; Voigt JJ; Pascal JP J Hepatol; 1989 May; 8(3):302-7. PubMed ID: 2732444 [TBL] [Abstract][Full Text] [Related]
10. Lack of effects of nifedipine on hepatic hemodynamics in patients with HBsAg-positive cirrhosis. Lay CS; Tsai YT; Kong CW; Lee FY; Lee SD; Lo KJ; Chiang BN; Chen KY Liver; 1987 Aug; 7(4):223-7. PubMed ID: 3683094 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients. Kawasaki S; Sugiyama Y; Iga T; Hanano M; Sanjo K; Beppu T; Idezuki Y Am J Gastroenterol; 1985 Oct; 80(10):801-6. PubMed ID: 4036939 [TBL] [Abstract][Full Text] [Related]
12. Drug disposition in patients with HBsAg-positive chronic liver disease. Villeneuve JP; Thibeault MJ; Ampelas M; Fortunet-Fouin H; LaMarre L; Côté J; Pomier-Layrargues G; Huet PM Dig Dis Sci; 1987 Jul; 32(7):710-4. PubMed ID: 3595383 [TBL] [Abstract][Full Text] [Related]
13. Effects of ranitidine on plasma clearance of indocyanine green in patients with liver cirrhosis. Kosaka Y; Tameda Y; Okita K; Takemoto T; Sato S; Okuda K; Kameda H; Yamamoto S; Kamada T; Muto Y Gastroenterol Jpn; 1987 Dec; 22(6):737-42. PubMed ID: 3443254 [TBL] [Abstract][Full Text] [Related]
14. Indocyanine green elimination in patients with liver disease and in normal subjects. Burns E; Triger DR; Tucker GT; Bax ND Clin Sci (Lond); 1991 Feb; 80(2):155-60. PubMed ID: 1848168 [TBL] [Abstract][Full Text] [Related]
15. [Liver metabolism of indocyanine green and aminopyrine in liver cirrhosis: relations with functioning liver cell mass]. Bolognesi M; Merkel C; Angeli P; Caregaro L; Gatta A Minerva Med; 1988 Dec; 79(12):1035-41. PubMed ID: 3211355 [TBL] [Abstract][Full Text] [Related]
16. Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green. Williams RL; Blaschke TF; Meffin PJ; Melmon KL; Rowland M Clin Pharmacol Ther; 1976 Sep; 20(3):290-9. PubMed ID: 954351 [TBL] [Abstract][Full Text] [Related]
17. Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics. Huet PM; Lelorier J Clin Pharmacol Ther; 1980 Aug; 28(2):208-15. PubMed ID: 7398188 [TBL] [Abstract][Full Text] [Related]
18. Effect of cimetidine on verapamil disposition. Loi CM; Rollins DE; Dukes GE; Peat MA Clin Pharmacol Ther; 1985 Jun; 37(6):654-7. PubMed ID: 4006365 [TBL] [Abstract][Full Text] [Related]
19. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. Kawasaki S; Sugiyama Y; Iga T; Hanano M; Beppu T; Sugiura M; Sanjo K; Idezuki Y Clin Pharmacol Ther; 1988 Aug; 44(2):217-24. PubMed ID: 3396264 [TBL] [Abstract][Full Text] [Related]
20. Plasma elimination of indocyanine green in the intact pig after bolus injection and during constant infusion: comparison of spectrophotometry and high-pressure liquid chromatography for concentration analysis. Ott P; Keiding S; Bass L Hepatology; 1993 Dec; 18(6):1504-15. PubMed ID: 8244277 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]